InvestorsHub Logo
Followers 0
Posts 283
Boards Moderated 0
Alias Born 09/26/2012

Re: None

Monday, 12/10/2012 5:38:06 PM

Monday, December 10, 2012 5:38:06 PM

Post# of 130743
Those Tweets on 12/10/12.

EPGL Med @EPGLMed
David T. Markus PhD is now Vice President, BioMems Development for EPGL.



EPGL Med @EPGLMed
* EPGL owns unique IP and know-how in BioMems with several applications currently in development.



EPGL Med @EPGLMed
Biomedical, MicroElectroMechanical Systems (BioMems) will become a core focus for EPGL moving forward.



EPGL Med @EPGLMed
Select EPGL team members concluded meetings in Irvine, CA last week regarding BioMems technology.

If you remembered last week on 12/5/12 they mentioned:

OTC update progressing. EPGL will be OTC "Current Information" shortly before year end.


"Select EPGL team members concluded meetings in Irvine, CA last week regarding BioMems technology."
"Biomedical, MicroElectroMechanical Systems (BioMems) will become a core focus for EPGL moving forward."
* The potential that they have and how they have been hinting us on their progress... this will be extremely beneficial financially to all of us who have strong holdings and are prepared for the ride.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.